Katie Abouzahr, M.D., is Vice President, Autoantibody (AAb) Portfolio and Maternal Fetal Disease Area Leader at Janssen Research and Development (R&D), LLC. In this role, Katie leads the development of assets in the AAb pathway portfolio and maternal fetal immunology disease area, of which includes Janssen’s lead investigative asset, nipocalimab, to address auto and alloantibody-driven diseases in multiple indications across maternal fetal, rare autoantibody, and prevalent rheumatology.
Katie joined Janssen in 2019 as a member of the Global Janssen R&D Strategy and Operations group and served as Vice President, Compound Development Team Leader (CDTL) for STELARA® (ustekinumab), Janssen’s largest commercialized product, overseeing its development in multiple indications and its lifecycle management strategy.
Prior to her work at Janssen, Katie served as a Principal at the Boston Consulting Group in London and Philadelphia for 12 years, where she worked on a range of engagements across the healthcare sector in the UK and US. Prior to that, she practiced as a Medical Doctor for the National Health Service (NHS) in London.
Katie received her Bachelor of Science in Chemical Pathology at Imperial College in London, and her Bachelor of Medicine, Bachelor of Surgery (MBBS) at Imperial College School of Medicine. She earned her Membership of the Royal College of Physicians of the UK in 2006.
Follow Katie on LinkedIn here.